United Kingdom

People: CRISPR Therapeutics AG (CRSP.OQ)

CRSP.OQ on NASDAQ Stock Exchange Global Market

17 Jul 2019
Change (% chg)

$0.25 (+0.52%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Woiwode, Thomas 

Dr. Thomas F. (Tom) Woiwode, Ph.D., has been Independent Director of CRISPR Therapeutics Ltd since April 2014. He has been with Versant Ventures since 2002, serving as a Venture Partner since 2008 and a Managing Director since 2014. He has served in a number of operating roles over this time, most recently as the Chief Operating Officer of Okairos, a biopharmaceutical company developing genetic vaccines for infectious diseases. He led the process that culminated in the sale of Okairos to GlaxoSmithKline. Prior to his role with Okairos, he co-founded EuroVentures, a wholly owned biotech incubator within Versant Ventures, and in this role, served as the founding Chief Business Officer for three biotech companies created within Versant: Flexion (public), Synosia (public, merged with BioTie), and Amira (acquired by Bristol-Myers Squibb). Prior to his role as a Venture Partner, he was a Principal at Versant Ventures and served on the boards of Antipodean, Metabolex and Saegis. He was a research scientist at XenoPort before joining Versant. He currently serves on the boards of Annapurna, Anokion, Audentes, CRISPR, Gritstone, Therachon and Kanyos Bio. He earned his PhD in Organic Chemistry as an NSF Fellow at Stanford University and graduated summa cum laude with a BA in English and received the Departmental Citation for his B.S. in Chemistry from UC Berkeley.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --